Perspective Therapeutics, Inc. earnings per share and revenue
On Jan 30, 2026, CATX reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -0.36 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 238.25 thousand, with a --% difference. The market reacted with a +11.81% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 8 analysts forecast an EPS of -0.38 USD, with revenue projected to reach 179.93 thousand USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were Perspective Therapeutics, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Perspective Therapeutics, Inc. reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Perspective Therapeutics, Inc.'s Q4 2025 earnings?
The stock price moved up 11.81%, changed from $2.54 before the earnings release to $2.84 the day after.
When is Perspective Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Apr 27, 2026.
What are the forecasts for Perspective Therapeutics, Inc.'s next earnings report?
Based on 8
analysts, Perspective Therapeutics, Inc. is expected to report EPS of -$0.38 and revenue of $179.93K for Q1 2026.